Background. Controversy still exists about the choice of aortic prosthesis
in elderly patients. This study investigates valve- and anticoagulant-relat
ed morbidity and mortality in elderly patients after aortic valve replaceme
nt (AVR) with a biologic (BP) or mechanical prosthesis (MP).
Methods. Between 1981 and 1995, 355 consecutive patients aged 70 years or o
lder (mean, 74 +/- 4 years; range, 70 to 87 years) underwent isolated AVR.
There were 222 (63%) replacements with an MP and 133 (37%) with a BP. Mean
follow-up was 3.7 +/- 2.8 years (range, 3 months to 15 years), with a total
follow-up of 1,214 patient-years.
Results. Hospital mortality was 7.6% (27 of 355), decreasing to 4.6% in the
last 3 years. There were 55 late deaths, 33 in patients with MF and 22 in
those with BP. At 10 years there was no significant difference between MP a
nd BP recipients in the actuarial estimates of survival (51% +/- 8% versus
33% +/- 13%), freedom from valve-related death (82% +/- 7% versus 72% +/- 1
2%), and freedom from thromboembolism (84% +/- 7% versus 94% +/- 3%). In co
ntrast, 10-year freedom from anticoagul-antrelated hemorrhages was 74% +/-
8% for Mr and 99% +/- 1% for BP (p = 0.02). Only 1 structural deterioration
occurred, in a patient with BP.
Conclusions. Satisfactory early results can be obtained in elderly patients
after AVR with both MP and BP. The comparable low late survival in the two
groups was predominantly influenced by non-valve-related deaths. A higher
incidence of anticoagulant-related hemorrhages limits the use of MP in elde
rly patients. Thus, in this population, BP should be preferred not just on
the basis of their expected longer durability, but mainly to avoid the risk
of anticoagulant-related hemorrhages. (C) 1998 by The Society of Thoracic
Surgeons.